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Rationale for the Study
Our study grew from an attempt to solve a controversy. In
1987 protein C antigen level was assessed in a large cohort
of healthy blood donors (1). Subjects in this cohort who
were heterozygous for protein C deficiency did not suffer
from venous thromboembolism. Family studies in four of
the protein C deficient individuals showed autosomal
inheritance of the defect. These findings seemed in contrast
with previous reports in which an association between
protein C deficiency and an increased incidence of venous
thromboembolism was found (2-4). The way in which
patients and normal subjects were selected for these studies
was thought to play a major factor in the explanation of the
differences that were found. In the first reports (2-4)
selected patients from families with a high frequency of
venous thromboembolism were investigated. This may have
resulted in a too high estimate of the risk of disease. In
contrast, Miletich et al. (1) investigated a normal popula-
tion, which does not lead to an estimate of the risk of
disease.
To solve the problem of the association of protein C
deficiency with venous thrombotic disease the Leiden
Thrombophilia Study (LETS) was started. It was designed
äs a large case-control study aimed at investigating
currently known and future risk factors for the development
of venous thromboembolism. In this way the role of a
deficiency of protein C, protein S or antithrombin and of
APC (activated protein C) resistance, elevated von
Willebrand factor and factor VIII:c levels, hyperhomo-
cysteinemia, and a recently detected mutation in the gene of
factor Π in relation to the risk of venous thromboembolism
could be established. Some of these had been in mind
before the study, others became important during the study.
One of the major contributions of the LETS to the field of
thrombophilia has been the assessment of APC resistance in
conjunction with the factor V Leiden mutation äs risk factor
for venous thrombosis.
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Study Design (5)
LETS was designed to assess the importance at the
population level of various risk factors for thrombosis,
many of which had been identified by family studies.
Generally, two approaches are possible: cohort studies and
case-control studies. In the former, patients with and
without a risk factor are followed over time, and absolute
risks (probability of disease, incidence) and relative risks
(incidence rate ratio) can be calculated. In a case-control
study, patients with thrombosis and healthy controls are
included, and relative risks (odds ratios) can be calculated.
Due to the rarity of the genetic risk factors for thrombosis,
a follow-up study of a truly unselected sample from the
population was considered unfeasible, and the case-control
design was chosen. A case-control design is perfectly
adapted for the study of genetic influences, since one cannot
imagine that cases or controls could be in any way selected,
except because of the disease that is studied. In contrast to
previous studies, rigid criteria were applied to minimize
misclassification, minimize selection bias, and maximize
power and reliability of the study. This included setting up
a System to identify all consecutive thrombotic events, and
to only include patients in whom the diagnosis was
objectively confirmed.
The organization of anticoagulant monitoring in the
Netherlands was important to achieve these goals. In the
Netherlands anticoagulation clinics (thrombosis Services) are
regionally organized. In this way all patients living in a
certain area are monitored for their oral anticoagulant
therapy by the same anticoagulation clinic, independent of
the hospital they were admitted to or the specialist or
general practitioner who started the treatment. Patients
participating in LETS were recruited from three thrombosis
Services in the Netherlands: Leiden, Amsterdam and
Rotterdam. A total of 474 (90% of eligible) consecutive
outpatients younger than 70 years and without a known
malignant disorder, with a diagnosis of a first, objectively
confirmed, deep vein thrombosis were included (Leiden
area: n=271, Amsterdam area: «=90, Rotterdam area: n =
113). Information about inclusion and exclusion criteria was
obtained from general practitioners, from discharge records
from the hospitals and from the records of the thrombosis
Services. Preferably, patients were seen after discontinu-
ation of oral anticoagulant therapy for at least three months.
Forty-eight (10%) of the 474 patients were on long-term
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oral anticoagulant therapy and were not allowed to Interrupt
their medication for various reasons.
Each patient was asked to find a healthy control subject
according to the following criteria: same sex, the same age
(+5 years), no biologic relationship, no history of venous
thromboembolism, no use of coumarin-derivatives for at
least 3 months and no known malignant disorders. Partners
of patients were also invited to volunteer äs control
subjects. When a patient was unable to find a control
subject, the first individual from the list of partners who
matched for age and sex was asked to join the study; 225
(47%) matched control subjects were partners of other
patients.
All subjects completed a Standard questionnaire about the
presence of acquired risk factors in a specific period prior
to the index date, i.e., the date of the thrombotic event.
Blood was collected and processed in the Standard fashion.
High-molecular-weight DNA was isolated from leucocytes
and stored at 4°C.
Analysis and Statistics
Relative risks were calculated äs estimates of the matched
odds ratio. The relative risk reflects the thrombosis risk for
a specific (category of a) risk factor relative to a reference
category (e.g., risk factor absent or lowest quartile).
Results
The mean age for patients and controls was 47 years (ränge
16-70 for patients, 16-73 for controls). The male/female
ratio among patients and controls was 3/4.
Protein C deficiency (5)
Lower limit of normal for protein C activity was set at
0.67 U/ml. For patients on stable long-term oral anti-
coagulant therapy protein C antigen was assessed by
electroimmunoassay (lower limit of normal 0.33 U/ml)3.
When one measurement of the protein C level was taken
into account (Table 1), the relative risk for the development
of venous thrombosis was 3.1 (95% CI 1.7-7.0). After
repeated testing the frequency of the defect was lower both
in patients and controls, and the relative risk became 3.8.
When the presence of a mutation was taken äs a criterion
for heterozygozity for protein C deficiency, the relative risk
became 6.5. For the categories of plasma protein C activity
levels, Table 2 shows an inverse relation between the
plasma level and the odds ratio for the development of
venous thrombosis. Depending on the applied criteria the
prevalence of protein C deficiency in the control group was
between 1.5 and 0.4%. These figures are in close
accordance with those reported by Miletich (1). In this
setting with patients and controls we found a clearly
increased risk of venous thrombosis in persons who are
heterozygous for the deficiency. The risk increased with
lower protein C activity levels. When stringent diagnostic
criteria were used the relative risk became 6.5, which is
probably the most reliable estimate of the relative risk of
thrombosis associated with hereditary protein C deficiency.
Tobte l Companson of prevalence and thrombosis risk in 474
patients and 474 control subjects for several defmitions for a pro-
tein C deficiency
Definition of protein C Patients Controls OR"·6 95% CI
deficiency (%) (%)
Ist measurement
<0.67 (0.33C) U/ml
2st+2nd measurement
<0.67 (0.33°) U/ml
Ist measurement
<0.67 (0.33°) U/ml
and the presence of a
mutation
22 (4.6) 7 (1.5) 3.1 1.7-7.0
15 (3.1) 4 (0.8) 3.8 1.3-10
13(2.7) 2(0.4) 6.5 1.8-24
"Denotes age- and sex-matched odds ratio.
bAH discordant patient-control pairs.
°Lower limit of normal for those on coumarin treatment.
Table 2 Thrombosis risk for categories of protein C activitity
levels3
Protein C strata Patientsb Controlsb ORC 95% CI
(U/ml)
<0.55
0.55-0.65
0.65-0.75
0.75-0.83
äO.85
4(4)
10(5)
16 (nd)
54 (nd)
342 (nd)
1(1)
3(1)
10 (nd)
44 (nd)
368 (nd)
4.0
3.7
1.8
1.3
1.0"
0.5-36
1.0-13
0.8-4.2
0.9-2.0
an=426 patient-control pairs without coumarin use (first measure-
ment).
bNumber of persons m whom a mutation was found (nd, not
done).
Test for trend, p <0.01.
dReference category.
Protein S deficiency (5)
The lower limit of normal for total protein S was set at
0.67 U/ml (0.33 U/ml for subjects on coumarin treatment)
and for free protein S at 0.57 U/ml. Slightly more control
subjects than patients were found with initial and persistent
low total protein S levels (Table 3). Thus, üo association
between low total protein S levels and thrombosis risk could
be detected. This striking result could not be explained by
the use of oral contraceptives. There was no difference in
the use of oral contraceptives between the female patients
(67%) and controls (73%) with low protein S levels. Using
a single free protein S assessment in the 426 patient-control
pairs that did not use oral anticoagulants, a relative risk for
thrombosis of 1.6 was found (95% CI 0.6-4.0). When both
total and free protein S levels below the lower limit of
normal were used äs criteria for protein S deficiency the
relative risk became 1.7 (95% CI 0.4-6.9). These results
are in contrast to reports in the literature where venous
thrombosis appears highly prevalent in kindreds with
protein S deficiency (6-8). Since we found two control
subjects with a persistent low protein S level at 0.50 U/ml,
a very low prevalence of protein S deficiency in the
population is not a likely explanation. The possibility that
the previous findings in families are at least partly the result
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Table 3 Prevalence and thrombosis risk in thrombosis patients and
control subjects for protein S and antithrombin deficiency
Table 4 Thrombosis risk for strata of APC-sensitivity ratios
Definition of a
deficiency
Total protein S:
Ist measurement
<0.67 (0.33") U/ml
lst+2nd measurement
<0.67 (0.33a) U/ml
Free protein Sd:
Ist measurement
<0.57 U/ml
Total and free
protein Sd:
Both below lower
limits of normal
Antithrombin:
Ist measurement
<0.80 U/ml
lst+2nd measurement
<0.80 U/ml
Patients
(%)
8 (1.7)
5(1.1)
13 (3.1)
5 (1.2)
20 (4.2)
5(1.1)
Controls
(%)
11 (2.3)
6 (1.3)
9 (2.1)
3 (0.7)
9(1.9)
1 (0.2)
OR
(95% CI)
0.7b (0.3-1.8)
0.8C (0.2-3.0)
1.6e (0.6-4.0)
1.7e (0.4-6.9)
2.2e (1.0-4.7)
5.0e (0.7-34)
"Lower limit of normal for those on coumarin treatment.
bSeventeen discordant patient-control pairs, in 7 of which the
patient had a lowered protein S level and the control subject did
not.
°Nine discordant patient-control pairs, in four of which the patient
had a lowered protein S level and the control did not.
dn=426 patient-control pairs not using oral anticoagulants.
CA1I discordant patient-control pairs.
of co-segregating additional genetic defects should be
considered seriously.
Antithrombin Deficiency (5)
The lower limit of normal was 0.80 U/ml. Based on one
measurement the relative risk on thrombosis for anti-
thrombin deficiency was 2.2 (95% CI 1.0-4.7). This figure
became 5.0 (95% CI 0.7-34) when it was based on two
consistently low measurements (Table 3).
The prevalence of low antithrombin levels is in agree-
ment with the literature, both for patients with thrombosis
äs for normal subjects (9,10). It can be concluded that
antithrombin deficiency is a rare disease, which probably
explains why the relative risk estimate of 5.0 in our study
did not reach statistical significance.
APC Resistance (11)
APC resistance was measured äs the ratio (APC sensitivity
ratio) of two activated partial thromboplastin times
(Cephotest, Nycomed Pharma, Oslo, Norway), one in the
presence and one in the absence of APC. Because low
levels of prothrombin, factor X, or both (<0.5 U/ml)
increase the APC-sensitivity ratio the test cannot be used in
patients on coumarin therapy.
From the total series of patients the first 345 consecutive
patients were included in this part of the study. Forty-two
patients were on oral anticoagulant therapy and two patients
APC-sensitivity ratio
&2.5
2.0-2.5
1.5-2.0
<1.5
Patients
163
84
36
18
Controls
220
72
7
2
ORa
1
1.6
7.4
12.0
95% CI
1.1-2.4
3.0-18
2.7-56
"Matched (crude) odds ratio; adjustment for VÜI:c, protein C, or
protein S concentrations or fibrinogen did not effect these results.
Test for trend: p<0.001.
had an initially prolonged APTT consistent with a lupus
anticoagulant. After exclusion of these 44 subjects the study
population consisted of 301 patient-control pairs. The lower
limit of normal was assessed at 2.17. Sixty-four (21%) of
the patients and 14 (5 %) of the control subjects showed a
APC-sensitivity ratio of less than 2.17. The relative risk of
venous thrombosis associated with the presence of APC
resistance was 6.6 (95% CI 3.6-12.0). In Table 4 it can be
seen that the risk of thrombosis increased with a decreasing
APC-sensitivity ratio.
The relatively high prevalence in the normal population
(5%) and the relative risk of nearly 7 for the development
of venous thrombosis makes APC resistance the most
prevalent hereditary risk factor for venous thrombosis
known today.
Factor V Leiden
Resistance to APC was found to be nearly always caused by
a guanine to adenine Substitution at nucleotide 1,691 in the
gene of blood coagulation factor V (12). This mutation
predicts the replacement of arginine at position 506 by
glutamine (FV Q506 or Factor V Leiden). The 64 patients
and their controls of the LETS study which were found to
have APC resistance were screened for the presence of the
mutation (13). Of the 70 subjects with APC resistance
(64 patients and 6 controls) 56 (53 patients and 3 controls)
were found to carry the mutation. Six of these (all patients)
were homozygous for the defect. In the 14 subjects in
which no mutation was detected, APC resistance was only
marginally abnormal. None of the 58 subjects without APC
resistance carried the mutation.
For patients homozygous for the factor V Leiden muta-
tion a relative risk of venous thrombosis of 80 was
calculated: because no homozygous individuals were found
among the controls, the relative risk was estimated
assuming Hardy-Weinberg equilibrium to calculate the
expected number of homozygous individuals in the general
population (13).
Oral contraceptives and the risk of venous thrombosis.
The use of oral contraceptive drugs increased the risk of
venous thrombosis 3.8-fold (95% CI 2.4-6.0) (14). It was
found that, in comparison to women not using the oral
contraceptive pill and without the factor V Leiden mutation,
the risk of venous thrombosis was 28.5 times higher in
women with the mutation and using the pill (14). The use
of pills containing the third generation progestagen
desogestrel led to a relative risk of venous thrombosis of
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8.7 in comparison to between 2.2 and 3.8 for anticon-
ceptive pills containing the other types of progestagens (15).
In a direct comparison between the oral contraceptives
containing desogestrel and 30 ^ g oestradiol and contra-
ceptives containing all other types of progestagens
combined, the age-adjusted relative risk was 2.5 (95% CI
1.2-5.2) (15).
Blood group, von Willebrand factor and factor VIH:c.
We investigated the putative role of blood groups, von
Willebrand factor and coagulation factor VIII (Factor
VIII :c) äs risk factor for the development of venous
thrombosis (16). A two-fold increase in the risk of venous
thrombosis for subjects with blood group non-O was found
in comparison to those with blood group O. Higher levels
of vWF and of factor VIII:c were associated with an
increased risk of thrombosis. After correction for the
influence of the other factors only factor VIII:c level
remained äs independent risk factor (Table 5). It is clear
from Table 5 that the level of factor VIII:c is an important
risk factor for the development of venous thrombosis: in
comparison to a level of FVIII.-c < lOOIU/dl a level of more
than 150IU/dl had a relative risk of 4.8. This high risk
stratum (factor VIII :c > 150 lU/dl) comprised 25% of the
patients and 11 % of the controls.
Table 6. Frequencies and thrombotic risk for the 20210 G/A
genotypes in the prothrombin gene
Genotype Patients
(M20210) (%)
Controls ORa 95% CI
GG
AG
AA
442
29
—
(93.8)
(6.2)
463
11
—
(97.7)
(2.3)
1
2,
,0"
.8 1.4-5.6
"Adjustment for age and sex, current pill use (yes/no), body mass
index, in menopause (yes/no) and smokmg (yes/no) did not affect
these results.
bReference category.
Table 7. Thrombosis risk and prothrombin level
Prothrombin Patients3 Controls Total
activity («=426) («=474) («=900)
(U/ml) (%) (%) (%)
ORb 95% CI
<0.95
0.95-1.04
1.05-1.15
>1.15
85 (20)
107 (25)
102 (24)
132 (31)
134 (28)
125 (26)
118 (25)
97 (20)
219 (24)
232 (26)
220 (24)
229 (25)
1.0C
1.3
1.4
2.1
0.9-2.0
0.9-2.0
1.5-3.1
aPatients on coumarin treatment excluded (n=48).
bTest for trend, /><0.001.
°Reference category.
Hyperhomocysteinemia (17)
In the subgroup of patients and controls who were seen at
the Leiden Anticoagulation Clinic, the total plasma homo-
cysteine level was assessed. Hyperhomocysteinemia was
defined äs a homocysteine level above the 95th percentile
in the control group (18.5 μιηοΙ/L). Of the 269 patients 28
(10%) had elevated plasma homocysteine levels äs
compared with 13 of the controls [matched odds ratio 2.5
(95% CI 1.2-5.2)]. The association between elevated
homocysteine levels and thrombosis increased with age and
was stronger among women than among men.
Table 5. Adjusted thrombosis risk for blood group and for cate-
gories of vWF and factor VIII
Risk factor Odds ratioadjusted 95% CI
Blood group (non-O vs O)a 1.5 1.0-2.2
vWF:Ag stratab
(lU/dl)
FVHI:c stratac
(lU/dl)
<100
100-125
125-150
S: 150
<100
100-125
125-150
3*150
1
1.1
1.3
1.2
1
2.3
3.0
4.8
0.7-1.9
0.7-2.2
0.6-2.1
1.3-3.8
1.6-5.7
2.3-10
aAdjustment for vWF:Ag and FVffl:c levels.
bAdjustment for blood group and FVIII:c levels.
"Adjustment for blood group and vWF:Ag levels.
Factor II (G20210A)
Very recently, a new risk factor for venous thrombosis was
found (18). A G to A transition at nucleotide position 20210
in the 3' untranslated region of the prothrombin gene was
found to be associated with increased levels of prothrombin
activity and with the occurrence of venous thrombosis. In
the LETS study population the prevalence of carriers of the
20210 A allele was 2.3% in the healthy controls and 6.2%
in the patients (18). This indicates a relative risk of
thrombosis of 2.8 (Table 6). In a series of selected patients
with a personal and family history of venous thrombosis the
mutation was found in 18% (18). Also, an association could
be shown between prothrombin levels and the risk of
thrombosis (Table 7). Although it is unclear how the
mutation of G20210 A leads to higher prothrombin levels,
these data suggest that the prothrombin level is the effector
of the thrombosis risk. Possibly other factors can also be
involved in elevated prothrombin levels.
Conclusions
The relative risk of venous thrombosis in the population äs
a whole was assessed for a number of hereditary abnor-
malities by a population based case-control study. The
application of rigorous methodology, i.e., the inclusion of
consecutive patients, and the inclusion only of objectively
confirmed thrombosis, made it possible to reliably assess
the importance of a variery of risk factors for thrombosis in
the general population. A case-control study is eminently
suited for the study of (rare) genetic risk factors since one
cannot imagine that cases and controls could be selected
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genetically, except because of the presence of the disease.
Moreover, genetic risk factors can still be measured "after"
the event, in contrast to many lifestyle risk factors. Only
for frequent genetic risk factors (like the factor V Leiden
mutation) would a foolw-up study be feasible. Even then,
a case-control approach might be more cost-efficient.
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